Skip to content

S. 1522 · 118th Congress (2023–2025)

A bill to require the Secretary of Health and Human Services to conduct a study on the designation of biosimilar biological products as interchangeable.

This bill requires the Food and Drug Administration to report on its designation of biosimilars as interchangeable, including the applicable standards, authorities, evidence, and other factors involved in such designations. (Biosimilars that are designated as interchangeable may be substituted for the reference product at a pharmacy without a new prescription, depending on state pharmacy laws.)

Expired in Senate committee

Derived from the legislative history, not an official disposition.

Latest actionReferred to committee

This bill’s path

This is S. 1522’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed Senate

  3. Passed House

  4. Sent to President

  5. Signed into law

  6. Expired

Sponsor
Sen. Roger Marshall (R-KS)
Policy area
Health

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in Senate

    Document: Introduced in Senate

    Sources
  2. Latest

    Referred to committee

    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

    Sources
  3. Expired

    Introduced → Referred to Senate Health, Education, Labor, and Pensions → No further action before the 118th Congress ended.

Committees

  1. SenateHealth, Education, Labor, and PensionsReferred May 10, 2023

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in Senate
Titles (1)
  1. A bill to require the Secretary of Health and Human Services to conduct a study on the designation of biosimilar biological products as interchangeable.

    Display title, Official title · Introduced in Senate